Introduction
Dual-antiplatelet therapy consisting of aspirin and clopidogrel is currently the therapy of choice to prevent thrombosis after percutaneous coronary intervention (PCI). A considerable interindividual variability in response to clopidogrel has been observed after administration of loading doses of clopidogrel. In a significant proportion of patients (10%–30%), no or little inhibition of platelet aggregation is achieved with the currently used dosing regimens. Some authors suggest that the antiplatelet effect achieved with the currently recommended maintenance dose can be augmented. In fact, administration of a 150-mg daily maintenance dose is now broadly discussed and occasionally used in clinical practice.
Introduction
Dual-antiplatelet therapy consisting of aspirin and clopidogrel is currently the therapy of choice to prevent thrombosis after percutaneous coronary intervention (PCI). A considerable interindividual variability in response to clopidogrel has been observed after administration of loading doses of clopidogrel. In a significant proportion of patients (10%–30%), no or little inhibition of platelet aggregation is achieved with the currently used dosing regimens. Some authors suggest that the antiplatelet effect achieved with the currently recommended maintenance dose can be augmented. In fact, administration of a 150-mg daily maintenance dose is now broadly discussed and occasionally used in clinical practice.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
